Form 4: Stereotaxis Director Fischel Granted 46,948 RSUs

Stereotaxis, Inc. Director and 10% Owner Nathan Fischel was granted 46,948 restricted share units, increasing his direct beneficial ownership.

Summary

• Nathan Fischel, a Director and 10% Owner of Stereotaxis, Inc. (STXS), was granted 46,948 restricted share units (RSUs).
• The transaction date for this grant was January 2, 2026.
• Each restricted share unit represents a right to receive one share of common stock.
• The RSUs vest on the earliest of: the fifth anniversary of the award date, termination of director service, or a Change of Control.
• Following this transaction, Nathan Fischel directly beneficially owns 677,672 shares of common stock.
• Additionally, 13,680,554 shares of common stock are indirectly beneficially owned through funds managed by DAFNA Capital Management LLC, where Dr. Fischel serves as Chief Executive Officer.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents an increase in insider ownership and aligns director interests with shareholders, though it's a routine compensation event.

Positives

• The grant of restricted share units aligns the director's interests with those of shareholders by linking compensation to future company performance and share value.
• An increase in direct beneficial ownership by a director and 10% owner can be viewed positively as it demonstrates continued commitment to the company.

Negatives

• The grant of restricted share units, upon vesting, will result in a slight dilution of existing shareholder equity, although this is a common form of compensation.

Risks

• The value of the restricted share units is subject to the future market price of Stereotaxis, Inc. common stock.
• Vesting conditions tied to service or a Change of Control introduce uncertainty regarding the exact timing of share receipt.

Future Outlook

The grant of restricted share units indicates a future increase in Nathan Fischel's direct shareholding upon vesting, which is contingent on continued service, a change of control, or the fifth anniversary of the award date.

Industry Context

The grant of restricted share units to a director is a standard practice in the biotechnology and medical device industry for executive and director compensation, aiming to incentivize long-term commitment and performance.

Comparison to Industry Standards

• The use of restricted share units (RSUs) as a component of director compensation is a common practice across publicly traded companies, including those in the medical technology sector, aligning with typical corporate governance standards.
• The vesting schedule, which includes a multi-year service requirement or a change of control clause, is consistent with compensation structures observed in comparable companies designed to retain key personnel and incentivize long-term value creation.

Corporate Governance

Related Party Transactions

• Nathan Fischel indirectly beneficially owns 13,680,554 shares through funds of which DAFNA Capital Management LLC is the investment manager and general partner. Dr. Fischel is the Chief Executive Officer of DAFNA Capital Management, LLC.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of RSUs, but also increased alignment of director's interests with long-term share performance.
• Director (Nathan Fischel): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The restricted share units will vest on the earliest of the fifth anniversary of the award date (January 2, 2031), the termination of the director's service on the board, or a Change of Control.

Key Dates

Recommendation

The filing details a routine grant of restricted share units to a director as part of their compensation. While it increases insider ownership, it does not present new information that would fundamentally alter the investment thesis for Stereotaxis, Inc. Therefore, a 'hold' recommendation is appropriate as it maintains current positions without new catalysts for buying or selling.

Keywords

Stereotaxis, STXS, Form 4, insider transaction, restricted share units, RSU, beneficial ownership, director compensation, equity grant